

Ultimaster™ Tansei™

Sirolimus Eluting Coronary Stent System

丹誠



MASTERING
COMPLEXITY.
SIMPLE.

 **TERUMO**
INTERVENTIONAL
SYSTEMS

Ultimaster™ Tansei™

Sirolimus Eluting Coronary Stent System

PRODUCT SPECIFICATIONS

Stent specifications		Delivery system specifications	
Stent design	Open cell	Guidewire compatibility	0.014" (0.36 mm)
Stent material	Cobalt Chromium L605	Low compliant balloon	Material Nylon 12
Strut thickness	80 µm	Nominal pressure	9 atm
Cell size (for 3 mm stent)	4.57 mm ²	Rated burst pressure	16 atm - 2.25 to 3.0 mm 14 atm - 3.5 to 4.0 mm
Drug	Sirolimus	Entry profile	0.018" (0.45 mm)
Drug dose	3.9 µg/mm stent length	Crossing profile	0.044" (1.12 mm) for 3.0 mm
Polymer	Poly (DL-lactide-co-caprolactone)	Shaft	Distal - 2.7 Fr (0.89 mm) Proximal - 1.9 Fr (0.64 mm)
Coating	Abluminal & gradient	Coating	Hydrophilic - Distal shaft
Polymer degradation time and drug release	3-4 months	Minimum Guide catheter	5 Fr (0.056"/1.42 mm)
		Usable length	144 cm

New length for more accurate lesion sizing

Item specifications

LENGTH (MM)	DIAMETER (MM)					
	2.25	2.50	2.75	3.00	3.50	4.00
9	DE-RQ2209KSM	DE-RQ2509KSM	DE-RQ2709KSM	DE-RQ3009KSM	DE-RQ3509KSM	DE-RQ4009KSM
12	DE-RQ2212KSM	DE-RQ2512KSM	DE-RQ2712KSM	DE-RQ3012KSM	DE-RQ3512KSM	DE-RQ4012KSM
15	DE-RQ2215KSM	DE-RQ2515KSM	DE-RQ2715KSM	DE-RQ3015KSM	DE-RQ3515KSM	DE-RQ4015KSM
18	DE-RQ2218KSM	DE-RQ2518KSM	DE-RQ2718KSM	DE-RQ3018KSM	DE-RQ3518KSM	DE-RQ4018KSM
21	DE-RQ2221KSM	DE-RQ2521KSM	DE-RQ2721KSM	DE-RQ3021KSM	DE-RQ3521KSM	DE-RQ4021KSM
24	DE-RQ2224KSM	DE-RQ2524KSM	DE-RQ2724KSM	DE-RQ3024KSM	DE-RQ3524KSM	DE-RQ4024KSM
28	DE-RQ2228KSM	DE-RQ2528KSM	DE-RQ2728KSM	DE-RQ3028KSM	DE-RQ3528KSM	DE-RQ4028KSM
33	DE-RQ2233KSM	DE-RQ2533KSM	DE-RQ2733KSM	DE-RQ3033KSM	DE-RQ3533KSM	DE-RQ4033KSM
38	DE-RQ2238KSM	DE-RQ2538KSM	DE-RQ2738KSM	DE-RQ3038KSM	DE-RQ3538KSM	DE-RQ4038KSM

Recommended DES in ESC/EACTS 2014 guidelines¹

1 MONTH DAPT*
CE mark approved for patients in need²

*Patients should be maintained on clinically adequate post-procedural antiplatelet therapy according to the current guidelines. In case of need, dual antiplatelet therapy can be discontinued earlier, but not before one month.

1. Windecker S et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014 Oct 1;35(37):2541-619.

2. Ultimaster IFU.

Ultimaster™ Tansei™ is not available for sale in all countries. Please contact your Terumo local sales representative for more information.

TERUMO
INTERVENTIONAL
SYSTEMS

Terumo Asia Holdings Pte. Ltd. 300
Beach Road #33-03 The Concourse
Singapore 199555
TEL +65-6-295-1792
FAX +65-6-294-2329

Terumo Korea Corporation
23rd Fl., GT Tower, 411 Seocho-daero,
Seocho-gu Seoul, 06615 Korea
TEL +82-2-565-9225
FAX +82-2-565-9224

RX ONLY. Refer to the product labels and package insert for complete warnings, precautions, potential complications, and instructions for use.

©2021 Terumo Asia Holdings. All rights reserved.
All brand names are trademarks or registered trademarks of Terumo.